Abstract:BACKGROUND:Drug resistance is an important cause of death for most patients with chronic myeloid leukemia (CML). The bone marrow microenvironment is believed to be mainly responsible for resistance to BCR-ABL tyrosine kinase inhibitors. The mechanism involved, however, is still unclear.METHODS:Bioinformatic analysis from GEO database of AKR1C3 was utilized to identify the AKR1C3 expression in CML cells under bone marrow microenvironment. Western blot and qPCR were performed to detect the AKR1C3 expression in two CML cell lines K562 and KU812 cultured +/- bone microenvironment derived stromal cells. CCK-8, soft agar colony assay, and Annexin V/PI assay were performed to detect the sensitivity of CML cells (K562 and KU812) to Imatinib under a gain of or loss of function of AKR1C3 treatment. The CML murine model intravenous inoculated with K562-OE-vector and K562-OE-AKR1C3 cells were established to estimate the effect of AKR1C3 inhibitor Indomethacin on Imatinib resistance. The bioinformatic analysis of miRNA databases was used to predict the potential miRNAs targeting AKR1C3. And the luciferase assay was utilized to validate the target relationship between miR-379-5p and AKR1C3. And, the soft agar colony assay and Annexin V/PI were used to validate the effect of miR-379-5p in AKR1C3 induced Imatinib resistance.RESULTS:In present study, we investigated AKR1C3 was highly expressed in CML under bone marrow microenvironment. AKR1C3 decreased Imatinib activity in K562 and KU812 cells, while inhibition of AKR1C3 could enhance Imatinib sensitivity in vitro study. Furthermore, murine model results showed combination use of AKR1C3 inhibitor Indomethacin effectively prolong mice survival, indicating that AKR1C3 is a promising target to enhance Imatinib treatment. Mechanically, AKR1C3 was found to be suppressed by miR-379-5p, which was down-expression in bone marrow microenvironment. Besides, we found miR-379-5p could bind AKR1C3 3'UTR but not degrade its mRNA level. Further, gain of miR-379-5p rescued the imatinib resistance induced by AKR1C3 overexpression in CML cells.CONCLUSIONS:Altogether, our study identifies a novel signaling regulation of miR-379-5p/AKR1C3/EKR axis in regulating IM resistance in CML cell, and provides a scientific base for exploring AKR1C3 as a biomarker in impeding IM resistance in CML.

ABL SH3 mutant inhibits BCR-ABL activity and increases imatinib sensitivity by targeting RIN1 protein in CML cell

The Novel Anticancer Agent JNJ-26854165 is Active in Chronic Myeloid Leukemic Cells with Unmutated BCR/ABL and T315I Mutant BCR/ABL Through Promoting Proteosomal Degradation of BCR/ABL Proteins

P19ink4d Inhibits Proliferation and Enhances Imatinib Efficacy Through BCR-ABL Signaling Pathway in Chronic Myeloid Leukemia.

BCR-ABL triggers a glucose-dependent survival program during leukemogenesis through the suppression of TXNIP

Imatinib blocks tyrosine phosphorylation of Smad4 and restores TGF-β growth-suppressive signaling in BCR-ABL1-positive leukemia

The Chimeric Ubiquitin Ligase SH2-U-box Inhibits the Growth of Imatinib-Sensitive and Resistant CML by Targeting the Native and T315I-mutant BCR-ABL

Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cells

A small molecule significantly inhibits the bcr/abl fusion gene at the mRNA level in human chronic myelogenous leukemia.

AKR1C3 Decreased CML Sensitivity to Imatinib in Bone Marrow Microenvironment Via Dysregulation of Mir-379-5p.

SHC004-221A1, a Novel Tyrosine Kinase, Potently Inhibits T315I Mutant BCR-ABL in Chronic Myeloid Leukemia

AHI-1 Interacts with BCR-ABL and Modulates BCR-ABL Transforming Activity and Imatinib Response of CML Stem/progenitor Cells

Recent Advances In Bcr-Abl Tyrosine Kinase Inhibitors For Overriding T315i Mutation

Target Inhibition of CBP Induced Cell Senescence in BCR-ABL- T315I Mutant Chronic Myeloid Leukemia

Inhibition of CHK1 Enhances Cell Death Induced by the Bcl-2-Selective Inhibitor ABT-199 in Acute Myeloid Leukemia Cells

Blockade of the Interaction Between Bcr-Abl and Ptb1b by Small Molecule Sbf-1 to Overcome Imatinib-Resistance of Chronic Myeloid Leukemia Cells

Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML)

Targeting cytohesin-1 suppresses acute myeloid leukemia progression and overcomes resistance to ABT-199

Targeting the PTP1B‐Bcr‐Abl1 interaction for the degradation of T315I mutant Bcr‐Abl1 in chronic myeloid leukemia

Abstract 3915: PBA2, a dual BCR-ABL and GSK3βkinases inhibitor, represses a wide array of Imatinib resistant cell lines in chronic myeloid leukemia

Proliferation inhibition and apoptosis induction of imatinib-resistant chronic myeloid leukemia cells via PPP2R5C down-regulation

Combination of an aurora kinase inhibitor and the ABL tyrosine kinase inhibitor asciminib against ABL inhibitor-resistant CML cells